Biocorp is an expert in connectivity but develops and manufactures both connected and non-connected injectable drug delivery devices. In addition to its own connected delivery devices it also offers add-ons for existing respiratory and parenteral drug delivery systems.
Biocorp develops and manufactures both connected and non-connected drug delivery devices. It is an expert in connectivity, developing its own connected delivery devices and also add-ons for existing respiratory and parenteral drug delivery systems.
Its “non connected” drug delivery devices include the Newguard passive safety system, the Biopass reconstitution system, and a range of container closures.
In the area of connectivity the company offers Datapen, a connected injection pen, and OneJet, a connected autoinjector. Easylog is an add-on to connect existing injection devices, and Inspair is an add-on to connect existing inhalers.
The company offers a large range of services including digital & physical design, device development, and product manufacturing.
Biocorp is vertically integrated and features:
- A manufacturing unit dedicated to the production of its devices and also devices for pharmaceutical companies
- A device R&D unit that develops innovative devices for the packaging, reconstitution and delivery of drugs
- An IT R&D unit specialised in health data encryption and management, as well as mobile and web app development.
Biocorp has been in business for more than 20 years and its stock is publicly traded in on the Paris Stock Exchange.
In June 2023, Novo Nordisk (Bagsværd, Denmark), which had been collaborating with Biocorp since 2021, announced it intended to acquire Biocorp, initially by acquiring a controlling stake in the company from its main shareholder, BIO JAG, followed by a mandatory simplified tender offer on all remaining outstanding shares.